DDInter1765 DDInter1376
Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Teniposide {u} (Compound) resembles {v} (Compound) Podofilox
Teniposide {u} (Compound) treats {v} (Disease) lung cancer
Teniposide {u} (Compound) binds {v} (Gene) CYP2C9
Teniposide {u} (Compound) upregulates {v} (Gene) EDEM1
Teniposide {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Teniposide {u} (Compound) downregulates {v} (Gene) CLTC
Teniposide {u} (Compound) causes {v} (Side Effect) Flushing
Teniposide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delavirdine
Teniposide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Grepafloxacin
Teniposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levodopa
Teniposide (Compound) resembles Podofilox (Compound)
Teniposide (Compound) treats lung cancer (Disease)
Teniposide (Compound) binds CYP2C9 (Gene)
Teniposide (Compound) upregulates EDEM1 (Gene)
Teniposide (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Teniposide (Compound) downregulates CLTC (Gene)
Teniposide (Compound) causes Flushing (Side Effect)
Teniposide may cause a minor interaction that can limit clinical effects when taken with Delavirdine
Teniposide may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Levodopa